Ezetimibe/simvastatin

Expert Opinion on Drug Safety

Volumn 8, Issue 6, 2009, Pages 715-725

  Montecucco, Fabrizio ^a   Quercioli, Alessandra ^b   MacH, François ^b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Atherosclerosis; Ezetimibe; Safety; Simvastatin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; CYTOCHROME P450 3A4; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PRAVASTATIN; RHO FACTOR; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; AMINOTRANSFERASE BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AORTA STENOSIS; AORTA VALVE STENOSIS; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED CANCER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FLATULENCE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOMODULATION; ISCHEMIA; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; MYOPATHY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERIPHERAL NEUROPATHY; PLEIOTROPY; PROSTATE CANCER; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VASODILATATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG COMBINATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; SIMVASTATIN;

EID: 70449470013     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903282745     Document Type: Review

References (107)

1. Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev 2009;(3): CD002091
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-1009
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-1389
4. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349-1357
6. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307
7. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J AmColl Cardiol 2005;46:1855-1862
8. Davidson MH. Clinical significance of statin pleiotropic effects: Hypotheses versus evidence. Circulation 2005;111:2280-2281
9. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235
10. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-1965
11. Shishehbor MH, Brennan ML, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003;108:426-431
12. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998;97:1129-1135
13. Kleemann R, Princen HM, Emeis JJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: Evidence for antiinflammatory effects of rosuvastatin. Circulation 2003;108:1368-1374
14. Montecucco F, Mach F. Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol 2009; DOI 10.1007/s00281-009- 0150-y
15. Alsheikh-Ali AA, Karas RH. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials. Curr Atheroscler Rep 2009;11:100-104
16. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-1762
17. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303:1201-1204
18. Dembowski E, Davidson MH. Statin and ezetimibe combination therapy in cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2009;16:183-188
19. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-1443
20. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359:1343-1356
21. Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:620-629
22. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-2134
23. Sudhop T, Reber M, Tribble D, et al. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res 2009. [Epub ahead of print]
24. Pedersen TR, Tobert JA. Simvastatin: A review. Expert Opin Pharmacother 2004;5:2583-2596
25. Mach F. Toward a role for statins in immunomodulation. Mol Interv 2002;2:478-480
26. Musial J, Undas A, Gajewski P, et al. Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia. Int J Cardiol 2001;77:247-253
27. Hernández-Perera O, Pérez-Sala D, Soria E, et al. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000;87:616-622
28. Henrich D, Seebach C, Wilhelm K, et al. High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. J Surg Res 2007;142:13-19
29. Spiel AO, Mayr FB, Leitner JM, et al. Simvastatin and rosuvastatin mobilize Endothelial Progenitor Cells but do not prevent their acute decrease during systemic inflammation. Thromb Res 2008;123:108-113
30. Liang YJ, Shyu KG, Wang BW, et al. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Cardiology 2008;110:182-190
31. Eccles KA, Sowden H, Porter KE, et al. Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 2008;200:69-79
32. Chen H, Ren JY, Xing Y, et al. Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: A dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol 2009;131:313-320
33. Naoum JJ, Zhang S, Woodside KJ, et al. Aortic eNOS expression and phosphorylation in Apo-E knockout mice: Differing effects of rapamycin and simvastatin. Surgery 2004;136:323-328
34. Liu PY. Liu YW, Lin LJ, et al. Evidence for statin pleiotropy in humans: Differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 2009;119:131-138
35. Veillard NR, Braunersreuther V, Arnaud C, et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006;188:51-58
36. Han KH, Ryu J, Hong KH, et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 2005;111:1439-1447
37. Montecucco F, Burger F, Pelli G, et al. Statins inhibit C-reactive protein-induced chemokine secretion, ICAM-1 upregulation and chemotaxis in adherent human monocytes. Rheumatology (Oxford) 2009;48:233-242
38. Day AP, Bellavia S, Jones OT, et al. Effect of simvastatin therapy on cell membrane cholesterol content and membrane function as assessed by polymorphonuclear cell NADPH oxidase activity. Ann Clin Biochem 1997;34:269-275
39. Deskur-Smielecka E, Wykretowicz A, Banaszak A, et al. The influence of treatment of hypercholesterolemic patients with simvastatin on plasma chemotactic activity and adherence of neutrophils. Int J Cardiol 2000;75:85-90
40. Rudich SM, Mongini PK, Perez RV, et al. HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant Proc 1998;30:992-995
41. Ghittoni R, Patrussi L, Pirozzi K, et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J 2005;19:605-607
42. Evans J, Powell JT, Schwalbe E, et al. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg 2007;34:302-303
43. Ferri N, Colombo G, Ferrandi C, et al. Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation. Arterioscler Thromb Vasc Biol 2007;27:1043-1049
44. Huang CY, Wu TC, Lin WT, et al. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. Eur J Clin Invest 2006;36:76-84
45. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-775
46. Hanefeld M, Marx N, Pfützner A, et al. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT Study. J Am Coll Cardiol 2007;49:290-297
47. Arnaud C, Burger F, Steffens S, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol 2005;25:1231-1236
48. Pearson T, Ballantyne C, Sisk C, et al. Comparison of effects of ezetimibe/ simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol 2007;99:1706-1713
49. van Heek M, Farley C, Compton DS, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134:409-417
50. Salen G, von Bergmann K, Lütjohann D, et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 2004;109:966-971
51. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-1754
52. Patrick JE, Kosoglou T, Stauber KL, et al. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Metab Dispos 2002;30:430-437 (Pubitemid 34263828)
53. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44:467-494
54. Davis HR Jr, Pula KK, Alton KB, et al. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Metabolism 2001;50:1234-1241
55. Mäki-Petäjä KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007;50:852-858
56. Pearson TA, Ballantyne CM, Veltri E, et al. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy. Am J Cardiol 2009;103:369-374
57. Kuhlencordt PJ, Padmapriya P, Rützel S, et al. Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Atherosclerosis 2009;202:48-57
58. Gomez-Garre D, Munoz-Pacheco P, Gonzalez-Rubio M, et al. Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol 2009; doi:10.1111/j.1476-5381.2008.00091.x
59. Capps N. Total and low-density lipoprotein cholesterol responses to ezetimibe in clinical practice. Int J Clin Pract 2006;60:867-869
60. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007;23:1169-1176
61. Ose L, Reyes R, Johnson-Levonas AO, et al. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: An exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007;29:2419-2432
62. Nakou ES, Filippatos TD, Kiortsis DN, et al. The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opin Pharmacother 2008;9:3151-863.
63. Tribble DL, Farnier M, Macdonell G, et al. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 2008;57:796-801
64. Tomassini JE, Mazzone T, Goldberg RB, et al. Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obes Metab 2009; doi:10.1111/j.1463-1326.2009.01061.x
65. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587-595
66. Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: The Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464-473
67. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-2134
68. Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: The VYTAL study. Mayo Clin Proc 2006;81:1579-1588
69. Farnier M, Averna M, Missault L, et al. Lipid-altering efficacy of ezetimibe/ simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Int J Clin Pract 2009;63:547-559
70. Stein EA. Additional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion? J Am Coll Cardiol 2008;52:2206-2209
71. Fleg JL, Mete M, Howard BV, et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: The SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008;52:2198-2205
72. Meaney A, Ceballos G, Asbun J, et al. The Vytorin on Carotid Intima-Media Thickness and Overall Arterial Rigidity (VYCTOR) Study. J Clin Pharmacol 2009;49:838-847
73. Sugrue DD, Trayner I, Thompson GR, et al. Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia. Br Heart J 1985;53:265-268
74. Reckless JP, Henry P, Pomykaj T, et al. Lipid-altering efficacy of ezetimibe/ simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: The INFORCE study. Int J Clin Pract 2008;62:539-554
75. Chenot F, Montant PF, Marcovitch O, et al. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest 2007;37:357-363
76. Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int 2003;63(Suppl 84):S207-10
77. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008;156:826-832
78. Gerdts E, Rossebo AB, Pedersen TR, et al. Impact of severity of aortic valve stenosis on effect of intensive lipid lowering therapy. Insights from the SEAS study. J Am Coll Cardiol 2009;53(10 Suppl A):A415
79. Mäki-Petäjä KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis. J Am Coll Cardiol 2007;50:852-858
80. Shirinsky IV, Zheltova OI, Solovyova NY, et al. Changes in disease activity, cytokine production, and proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis after simvastatin treatment. Scand J Rheumatol 2009;38:23-27
81. Hermann F, Forster A, Chenevard R, et al. Simvastatin improves endothelial function in patients with rheumatoid arthritis. J Am Coll Cardiol 2005;45:461-464
82. Westerweel PE, Visseren FL, Hajer GR, et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur Heart J 2008;29:2808-2817
83. Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, et al. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 2009;202:216-224
84. Olijhoek JK, Hajer GR, van der Graaf Y, et al. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: A randomized double-blind crossover trial. J Cardiovasc Pharmacol 2008;52:145-150
85. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. Circulation 2006;114:2788-2797
86. Law M, Rudnicka AR. Statin safety: A systematic review. Am J Cardiol 2006;97:52C-60C
87. MRC/BHF Heart Protection Study Collaborative Group. Effects of simvastatin 40mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009;9:6
88. Pasanen MK, Neuvonen M, Neuvonen PJ, et al. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 2006;16:873-879
89. Bradford PG, Awad AB. Phytosterols as anticancer compounds. Mol Nutr Food Res 2007;51:161-170
90. Mascitelli L, Ravnskov U, Pezzetta F, et al. After the failure of ENHANCEd cholesterol lowering in familial hypercholesterolemia, SEAS of problems with ezetimibe. Angiology 2009;60:127-128
91. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008;359:1357-1366
92. Pandor A. Ara R.M. Tumur I. et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: Systematic review and meta-analysis of randomized controlled trials J Intern Med 2009 265 568-8093.
93. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009;265:568-8093. Friedman GD, Flick ED, Udaltsova N, et al. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008;17:27-36
94. Halleck M, Davis HR, Kirschmeier P, et al. An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach. Toxicology 2009;258:116-130
95. Solomon KR, Pelton K, Boucher K, et al. Ezetimibe is an inhibitor of tumor angiogenesis. Am J Pathol 2009;174:1017-1026
96. Strony J, Yang B, Hanson ME, et al. Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: A randomized, 12-month double-blind extension study. Curr Med Res Opin 2008;24:3149-3157
97. van der Graaf A, Cuffie-Jackson C, Vissers MN, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2008;52:1421-1429
98. Strony J, Hoffman R, Hanson M, et al. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: Results from two open-label extension studies in hypercholesterolemic patients. Clin Ther 2008;30:2280-2297
99. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-741
100. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1092-1097
101. Davidson MH, Maccubbin D, Stepanavage M, et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006;97:223-228
102. Matsuzawa Y, Kita T, Mabuchi H, et al. Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatement with minimum side effects in 51,321 Japanese hypercholesterolemic patients. Circ J 2003;67:287-294
103. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intesive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 2004;292:1307-1316
104. Sirtori CR. Pharmacology and mechanism of action of the new HMG-CoA reductase inhibitors. Pharmacol Res 1990;22:555-563
105. Alsheikh-Ali AA, Karas RH. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 2005;8:95-97
106. Lipka L, Sager P, Strony J, et al. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004;21:1025-1032 (Pubitemid 40075727)
107. Alsheikh-Ali AA, Karas RH. Ezetimibe, and the combination of ezetimibe/ simvastatin, and risk of cancer: A post-marketing analysis. J Clin Lipidol 2009;3:138-142